This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Analyst Blog: Archive
SOFI Stock Skyrockets 82% in 6 Months: Buy, Hold or Sell?
by Shuvra Shankar Dey
SoFi's 82% surge in six months spotlights soaring profitability, record loan growth and sharply raised 2025 guidance that could keep momentum alive.
BACPositive Net Change JPMPositive Net Change SOFINegative Net Change
fin-tech finance
DIS' OpenAI Partnership Boosts AI Footprint: Time to Hold the Stock?
by Vasundhara Sawalka
Disney's $1 billion OpenAI deal expands its AI reach and content strategy, but mixed results and segment headwinds keep the stock in hold territory.
AMZNNegative Net Change NFLXNegative Net Change DISNegative Net Change PSKYPositive Net Change
artificial-intelligence consumer-discretionary internet-content
Broadcom Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Fall
by Zacks Equity Research
AVGO posts 37% EPS growth and 28% revenue jump in fiscal Q4, fueled by AI strength, but shares slip over 3% despite the beat.
APHPositive Net Change AVGONegative Net Change AEISPositive Net Change RDDTNegative Net Change
artificial-intelligence semiconductor tech-stocks
SkyWest's EPS Estimates Northbound: Should Investors Buy the Stock?
by Zacks Equity Research
With earnings estimates soaring high, we assess the investment potential of SKYW stock currently.
DALPositive Net Change UALPositive Net Change ALKPositive Net Change SKYWNegative Net Change
airlines transportation
APPS vs. PUBM: Which Stock Has an Edge in the AdTech Market?
by Subham Roy
Digital Turbine gains momentum while PubMatic shifts strategy amid changing DSP demand and tightening AdTech dynamics.
APPSNegative Net Change PUBMNegative Net Change
ad-tech advertising
Should Investors Hold Old Dominion Stock Despite Its Higher Valuation?
by Zacks Equity Research
With ODFL's shares moving south, we assess the current positioning of the stock to determine if it's a good investment at this juncture.
JBHTNegative Net Change ODFLNegative Net Change KNXNegative Net Change
transportation
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
RHHBYPositive Net Change BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Tesla's New Discounts on Model Y Help Boost Q4 Deliveries?
by Zacks Equity Research
TSLA's year-end discounts, free upgrades and 0% financing aim to lift Model Y demand as the company works to clear inventory and sustain momentum.
TSLAPositive Net Change NIONegative Net Change XPEVNegative Net Change
auto-tires-trucks electric-vehicles
Synopsys Q4 Earnings Surpass Estimates, Revenues Rise Y/Y
by Zacks Equity Research
SNPS posts a Q4 beat as revenues surge on strong Time-Based, Upfront Product and EDA growth, while offering upbeat FY26 and Q1 outlooks.
APHPositive Net Change NVDAPositive Net Change SNPSPositive Net Change COMMNegative Net Change
tech-stocks
Daktronics' Q2 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Fall
by Zacks Equity Research
DAKT tops Q2 estimates with strong earnings and revenue growth, boosted by rising orders and a surging product backlog.
APHPositive Net Change AEISPositive Net Change DAKTPositive Net Change APPSNegative Net Change
earnings tech-stocks
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform
by Zacks Equity Research
AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.
BSXNegative Net Change ISRGPositive Net Change ATRCNegative Net Change MEDPPositive Net Change
medical medical-devices
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Verizon's Empower Field Network Infrastructure Upgrade Aid Shares?
by Zacks Equity Research
VZ's Wi-Fi 6E upgrade at Empower Field boosts fan connectivity with 2,400 new access points and a faster, safer stadium network.
TNegative Net Change VZNegative Net Change TMUSPositive Net Change
internet iot mobile tech-stocks
Clorox's Brand Investments Are Up: Will They Translate to Growth?
by Zacks Equity Research
CLX leans on heavier brand investment and new product launches to rebuild momentum as ERP-related disruptions weigh on near-term sales.
COCONegative Net Change CLXNegative Net Change UNFINegative Net Change LWNegative Net Change
consumer-staples
DraftKings' iGaming Up 25%: A Second Growth Engine Emerging?
by Harendra Ray
DKNG's 25% iGaming surge signals a steadier growth engine as upgrades and stronger customer metrics lift third-quarter momentum.
MGMNegative Net Change DKNGPositive Net Change FLUTNegative Net Change
consumer-discretionary
Is Comfort Systems Positioned for Long-Term Pharma Project Demand?
by Amit Kr Ram
FIX sees rising pharma and life sciences planning activity, signaling a strong long-term pipeline for its specialized mechanical and electrical work.
WSONegative Net Change AAONNegative Net Change FIXPositive Net Change TGENNegative Net Change
construction
Can Flex Offset Automotive Headwinds in Its Reliability Segment?
by Vaishali Doshi
FLEX leans on data center surge to counter automotive softness in its Reliability segment's performance.
JBLNegative Net Change FLEXNegative Net Change CLSNegative Net Change
tech-stocks
Can PLAY's Revamped Remodel Blueprint Catalyze Its Next Growth Cycle?
by Mrithunjoy Kaushik
Dave & Buster's sharpens its remodel strategy with guest-first upgrades, aiming to boost traffic, productivity and fuel its Back to Basics momentum.
EATPositive Net Change QSRPositive Net Change PLAYNegative Net Change
restaurants retail
Suncor Unveils 2026 Guidance Focused on Growth & Superior Returns
by Zacks Equity Research
SU's 2026 guidance outlines higher production, strong refining utilization and a stronger commitment to shareholder returns backed by disciplined investments.
SUNegative Net Change CVENegative Net Change NGSNegative Net Change BTEPositive Net Change
energy oil-energy
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
by Zacks Equity Research
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSKPositive Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLPositive Net Change
biotechs
Will the CEC Acquisition Strengthen Sterling's Margin Profile in 2026?
by Amit Kr Ram
STRL's CEC acquisition boosts E-Infrastructure momentum and positions it for higher-value work and margin gains heading into 2026.
FLRNegative Net Change ACMNegative Net Change KBRNegative Net Change STRLPositive Net Change
construction
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
AZNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change MRKNegative Net Change
pharmaceuticals
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
by Zacks Equity Research
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
BSXNegative Net Change ATRCNegative Net Change PAHCPositive Net Change CBLLPositive Net Change
medical medical-devices
Fed Cuts Rate: Will This Accelerate Morgan Stanley's IB Fee Growth?
by Ronit Masi
A fresh Fed rate cut lifts optimism as Morgan Stanley stands to gain from rising deal-making and a stronger near-term investment banking backdrop.
GSPositive Net Change JPMPositive Net Change MSNegative Net Change
finance